“This process provides new manufacturers with established products the opportunity to quickly enter the VietNamese market and help with the COVID fight while also establishing themselves in a growing market of 100 million people.”

David Vo
General Manager
Asia Actual VietNam

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Sources and Links

VietNam Expedites Registration of COVID-19 Related Medical Devices

Published on: October 4th, 2021

With the release of Circular 13/2021/TT-BYT on September 16, 2021, the VietNamese Ministry of Health has provided a new, expedited review process for specified medical devices related to COVID-19. Qualifying applications will be reviewed in 10 days and will need to be renewed by the end of 2022. Products listed as essential to fighting COVID-19 and are eligible for an expedited registration route are:

  1. Extraction machine
  2. PCR machine
  3. Chemicals (biological products) used with the PCR machine to test for SARS-Co V-2
  4. Anti-SARS-Co V-2 antigen/antibody rapid test kits
  5. Invasive and non-invasive ventilators (high function, high flow, portable, etc.)
  6. Continuous dialysis machine
  7. Portable x-ray machine
  8. Color Doppler ultrasound machine (3 probes)
  9. Blood gas meter (measuring electrolytes, lactate, and hematocrits)
  10. Patient monitor (5 parameters)
  11. Electric injection pump
  12. Infusion machine
  13. Pacemaker/Defibrillator
  14. Electrocardiogram (6 channels)
  15. Portable ultrasound machine
  16. Coagulation time meter
  17. Hemodynamic meter

Qualifying Products

Not all products will be reviewed under the fast track, abbreviated review process in VietNam. Products must meet one of the following to submit under this registration route:

  1. Has been allowed to circulate or use by one of the following organizations (US FDA, TGA, Health Canada, MHLW, PMDA)
  2. It has been regulated by the competent authorities of the European countries specified in Appendix 2 to this Circular for permission for circulation and emergency use;
  3. Belonging to the list of SARS-CoV-2 testing products that are used urgently issued by the World Health Organization (WHO)
  4. Belonging to the list of popular products for testing SARS-CoV-2 due to issued by the European Health Security Committee (EUHSC)
  5. Having been granted a commercial import license in VietNam South before the effective date of this Circular
  6. Produced domestically in the form of technology transfer and meets criteria mentioned in points a) through e)
  7. Produced domestically in the form of processing for medical equipment economy and meets criteria mentioned in points a) through e)

This process provides new manufacturers with established products the opportunity to quickly enter the VietNamese market and help with the COVID fight while also establishing themselves in a growing market of 100 million people.

Come Grow With Us

Asia Actual specializes in helping medical device manufacturers grow their sales in Asia with experienced, bi-lingual commercial and regulatory experts on the ground in each market.

Contact Asia Actual today with any questions or support requests.

Blog Posts

China’s NMPA Updates Medical Device Classification Catalogue

China’s National Medical Products Administration (NMPA) maintains a list of all medical device categories called the Medical Device Classification Catalogue. NMPA published a notice on August 17, 2023, that they had released amendments to the Medical Device Classification Catalogue. It’s important for manufacturers to understand these changes as they can significantly impact the cost and time to register medical devices.
Read more

Thai FDA Drafting New Guidance for SaMD and AI Device Registration

Thai FDA is drafting new guidelines for AI Regulation. The novel characteristics of artificial intelligence (AI) software cause issues with the medical device registration process in most countries. The Thai Food and Drug Administration (Thai FDA) is working to address this important issue, most recently by hosting a meeting with interested parties on July, 2023, which Asia Actual Thailand employees were invited to attend.
Read more

China NMPA Adds 47 Products to Clinical Trial Exemption List

China’s National Medical Products Administration (NMPA) updated its clinical trial exemption list, adding 47 products. The NMPA updates this list every two to three years, with the last amendment in 2021. This brings the total number of clinical trial exempted product categories in China to 1,025.
Read more